73 Comparing FVIII concentration and activity Table 1. Patient characteristics. Number Percentage of total Total n = 87 100% Gender, male n = 85 98% Anti-FVIII antibodies (≥0.6 BU/mL) n = 5 6% (0.8-5.3 BU/mL) Samples ‘exposed’ to exogenous FVIII products n = 58 67% Samples ‘unexposed’ to exogenous FVIII products n = 29 33% Plasma-derived FVIII, full-length - Aafact® n = 7 8% Recombinant FVIII, full-length - octocog alfa, Advate® - octocog alfa, Helixate®/Kogenate® n = 26 - n = 8 - n = 18 30% - 9% - 21% Recombinant FVIII, B-domain modified - turoctocog alfa, NovoEight® - efmoroctocog alfa, Elocta ® n = 27 - n = 22 - n = 5 31% - 25% - 6% Mean SD Age (years) 37 22 Height (cm) (n = 72) 167 33 Body weight (kg) (n = 75) 69 31 Body Mass Index (kg/m2) (n = 72) 23 6 Abbreviations: FVIII: factor VIII; BU: Bethesda Units. Figure 1. Scatter plot of linear regression between FVIII plasma concentration (measured with LC-MS/ MS) compared to FVIII activity (measured with OSA). R2 of 0.81. Subgroups are illustrated with different symbols, see legend. 4

RkJQdWJsaXNoZXIy MTk4NDMw